Search the Newsreel

Cyclerion Therapeutics (CYCN) outlines two-step merger structure with Korsana Biosciences

Cyclerion Therapeutics (CYCN) has detailed a two-step merger with Korsana Biosciences, Inc. through a Form 425 SEC filing. The plan involves Cariboos Merger Sub Corp. merging into Korsana, making Korsana a wholly-owned subsidiary, followed by Korsana merging into Cariboos Merger Sub II, LLC. The …

Cyclerion Therapeutics Inc (CYCN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cyclerion Therapeutics (CYCN) outlines terms, risks and disclosures for proposed Korsana merger

Cyclerion Therapeutics (CYCN) has detailed the terms, risks, and disclosures for its proposed merger with Korsana Biosciences in a recent Form 425 SEC filing. The merger involves two Cyclerion subsidiaries merging with Korsana, with the transaction contingent on Cyclerion stockholder approval, regulatory clearances, and …

Cyclerion Therapeutics (NASDAQ: CYCN) outlines Korsana merger and going concern risk

Cyclerion Therapeutics (NASDAQ: CYCN) has reported its Q2 2026 financials, showing $1.391 million in cash and cash equivalents, a net loss of $4.932 million for the first half of 2026, and no revenue. The company has identified substantial doubt about its ability to continue …

Cyclerion Therapeutics 2Q 2026: Revenue $0 Net loss $(1.76M) — 10-Q Summary

Cyclerion Therapeutics reported zero revenue and a net loss of $(1.755M) for Q2 2026, a significant change from the previous year. The company is undergoing a merger with Korsana, expected to close in Q3 2026, and is focusing on pipeline monetization and specific drug …

Cyclerion (CYCN) and Korsana add leaders as reverse merger targets Q3 2026 close

Cyclerion Therapeutics (CYCN) and Korsana Biosciences announced progress on their reverse merger, which is still expected to close in Q3 2026. Korsana has strengthened its leadership team with new appointments, including Matthew Leoni as Chief Medical Officer, Gan Wei as Chief Technical Officer, and …

Cyclerion Therapeutics Inc (CYCN) Valuation: PE, PB & Fair Value Analysis

The article analyzes the valuation of Cyclerion Therapeutics Inc (CYCN), noting its current valuation score of 8.56, which ranks 84 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -2.63 and mentions that relevant data for …

Cyclerion Therapeutics Inc (CYCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cyclerion Therapeutics Inc (CYCN), evaluating its price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests a current price momentum score of 3.73, ranking it 331 out of 384 in its …

Cyclerion Therapeutics, Inc. SEC Filing (Jul 27, 2026)

This article reports on an SEC filing from Cyclerion Therapeutics, Inc. (CYCN), specifically an "EFFECT" filing with an effectiveness date of July 24, 2026. The filing is a Form S-4, related to a business combination registration. It also provides the company's stock overview, recent …

Cyclerion Therapeutics Inc (CYCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article focuses on the revenue breakdown for Cyclerion Therapeutics Inc (CYCN), highlighting that the company has not yet disclosed relevant data regarding its business segments or regional revenue and profit contributions. The page provides current stock performance details for CYCN, but the core …

CYCN|Cyclerion Therapeutics Inc|Price:3.475|Chg%:-0.025

This article provides an in-depth analysis of Cyclerion Therapeutics Inc (CYCN), highlighting its market trends, real-time quotes, and trading strategies. It details the company's financial performance, key figures, and a score indicating healthy fundamentals and high growth potential despite its valuation being considered fairly …

Cyclerion Therapeutics Inc (CYCN) Institutional Confidence

This article provides an overview of Cyclerion Therapeutics Inc (CYCN) and its institutional confidence score. It includes the stock's current trading price, market capitalization, and a table detailing institutional shareholdings and changes in shares held by various entities and individuals. The institutional confidence score …

Form 13D/A CYCLERION THERAPEUTICS For: 21 July By Investing.com

This article announces the filing of a Form 13D/A for Cyclerion Therapeutics (CYCN) on July 21. It is a brief, technical update from Investing.com, typical of financial news reporting on SEC filings. The article itself contains no additional commentary or details beyond the filing …

Cyclerion Therapeutics (CYCN) investor reports 19.4% stake and preferred share conversion

Peter M. Hecht has updated his beneficial ownership in Cyclerion Therapeutics, Inc. (CYCN), now holding 910,240 shares of Common Stock, representing 19.4% of the outstanding class. This change resulted from the forfeiture of options for 110,984 shares and the conversion of 351,037 non-voting Series …

Cyclerion Therapeutics (CYCN) director converts 351,037 preferred to common shares

Cyclerion Therapeutics director Peter M. Hecht converted 351,037 shares of Series A Convertible Preferred Stock into an equal number of Common Stock shares on July 16, 2026, eliminating all his preferred holdings. This transaction increased his direct common stock ownership to 910,240 shares, and …

Cyclerion Therapeutics (Nasdaq:CYCN) - Stock Analysis

This Simply Wall St analysis provides an overview of Cyclerion Therapeutics (CYCN), highlighting its biopharmaceutical focus on sGC stimulators for CNS and peripheral diseases. The report details the company's financial health, significant risks including declining earnings forecasts and cash runway issues, and recent corporate …

Cyclerion Therapeutics Inc. (CYCN) Q4 2025 Earnings: EPS Beat Driven by Disciplined Cost Management, Stock Declines - Dividend Earnings Report

Cyclerion Therapeutics (CYCN) Gains 6.6% as Shares Test Key Resistance Near $3.55 - Wave Extension

Cyclerion Therapeutics (CYCN) Q4 2025 Earnings: Narrower Loss Drives 6.62% Stock Surge as Pipeline Progress Continues - Earnings Per Share

CYCN Stock Explodes 313% on April 1 After Cyclerion-Korsana Merger Deal for Alzheimer's Pipeline

Cyclerion Therapeutics to Merge with Korsana Biosciences

Cyclerion Therapeutics (CYCN) Stock Price, News & Analysis

Cyclerion Therapeutics, Inc. (CYCN) stock price, news, quote and history

Should I buy Cyclerion Therapeutics (CYCN)